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Abstract  
Introduction: Obesity is a leading public health problem in the developed and developing 
world. As the prevalence of obesity and its associated comorbidities increases, the number of the 
medications used by individuals living with obesity is also on the rise. Beyond the utility of these 
drugs for the treatment of obesity-related chronic diseases, many have unwanted side effects, 
including weight gain. Objectives: To characterize the number of medications used by patients 
of the Wharton Medical Clinic (WMC) both overall and by obesity class, and; to determine 
whether the amount of weight change differs according to therapeutic drug classes or chronic 
condition. Methods: Data was derived from a subset of bariatric patients (n=1426) who attended 
WMC for 3+ months. Study exposures included the number and type of medications taken, and 
type of the chronic diseases experienced. The primary study outcome was relative weight 
change. Results: Of the 153 medications listed by WMC patients, 32 have side effects that 
include weight gain. Over 3 months of follow-up, average weight loss was 4.7 kg; percentage 
weight change was greatest amongst patients with a history of stroke (6.1%), heart attack (5.3%) 
and hypertension (4.8%). Implications: Barriers to weight loss may include pharmacological 
treatment for pre-existing conditions. These findings have implications for setting realistic 
weight loss goals for long-term obesity management.  
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Obesity and Medication Use 
Obesity is a leading public health problem in the developed and developing world (21). 
At present, approximately one-third of Canadian adults are at high risk of obesity-related disease, 
disability and premature death (5). As the prevalence of obesity and its associated comorbidities 
increases, the number of the medications prescribed, and used, by individuals living with obesity 
is also on the rise (8). Results of the 2007 to 2011 Canadian Health Measures Survey (CHMS) 
reported that 41% of individuals, 6 to 79 years old, had taken at least one prescription medication 
within two days of their household interview (36). At the same time, more than one in six 
middle-aged (45-64 y) Canadians (M: 18.9%; F: 11.5%) used lipid-modifying agents, 
combinations of different triglyceride and cholesterol reducers (44), and one in twelve (M: 
10.3%; F: 6.6%) used ACE inhibitors (37), which are used as a treatment for a variety of 
conditions, such as scleroderma, high blood pressure and migraines (24).  
Beyond the utility of these drugs for the treatment and management of each obesity-
related chronic disease, many have unwanted side effects, and some may even result in weight 
loss or gain through modulation of neurochemical and metabolic pathways. For instance, 
neuroleptic drugs (31), tricyclic antidepressant drugs (14), β Adrenergic Receptor Blockers (29) 
and thiazolidinediones (15) are known to induce weight gain, and Metformin (22) and 
Fenofibrate (23) are known to induce weight loss in regular users. In individuals with obesity-
related chronic disease who are trying to lose weight to normalize their risk profile, adjunctive 
therapy with some medications may therefore present a paradox of dampened effects. At present, 
it is not clear to what extent this may occur amongst patients in medically supervised weight loss 
programs, a high-risk subgroup of individuals living with obesity. 
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1.0 General Introduction 
In 2014, 5.3 million Canadian adults, aged 18 and older, were classified as obese (Body Mass 
Index (BMI) ≥ 30 kg.m-2). The rate of obesity in men increased from 20.1% in 2013 to 21.8% in 
2014, which is the highest obesity rate for men reported since 2003. The same increasing trend is 
seen amongst women from 2013 to 2014 (18.7%) and this rate is also significantly higher from 
2003 when it was 14.5% (33). Obesity is multifactorial and difficult to treat. Research has shown 
that only 20% of individuals defined as overweight (≥25 kg.m-2) are able to successfully 
maintain a 10% weight loss for at least 1 year (45). As the prevalence of obesity and its 
associated comorbidities increases, the number of the medications prescribed, and used, by 
individuals living with obesity is also on the rise (8). In addition to treating obesity and its related 
comorbidities, these medications may have unwanted side effects. Some of these medications 
may induce weight gain or weight loss while some are neutral. Individuals with obesity-related 
chronic diseases who are trying to lose weight to normalize their risk profile, adjunctive therapy 
with some medications may therefore present a paradox of dampened effects. This issue is 
particularly concerning in patients who are taking multiple medications, with different side 
effects. Better understanding of the possible association between different types of medications 
and chronic diseases with weight change is necessary so that more sustainable weight loss goals 
can be set for long term weight management.  
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2.0 Literature Review 
2.1 Effect of Weight Loss on Cardiovascular Disease  
In Canada, cardiovascular disease (CVD) is the 2nd leading cause of death (35), with 
more than 4 in 10 Canadians at an elevated risk for coronary heart disease (CHD) (32). 
Overweight and obesity are correlated with a variety of health conditions such as heart failure, 
CHD and sudden death associated with heart complications, and is an independent risk factor of 
for CVD (27). There is increasing evidence that even modest weight loss (5-10%) can 
fundamentally affect cardiovascular risk factors, and can lead to regression in coronary arterial 
lesions, cardiac events and to a decreased risk of cardiac mortality (41). For example, the 
Framingham Heart Study, a cohort study on residents of Framingham, Massachusetts, clearly 
illustrates that the rate of development of CVD is associated with the degree of overweight. After 
26 years of follow up in this study, each standard deviation increase in relative weight was 
associated with a 22% and 15% increases in cardiovascular complication in women and men, 
respectively (20). Moreover, the look AHEAD (Action For Health in Diabetes) study (n= 5,145, 
37% from ethnic/racial minorities, 40.5% male) on individuals with diabetes at baseline, living 
with overweight and obesity, investigated the association between the magnitude of weight loss 
and changes in CVD risk factors at 1 year. This secondary study illustrated that the magnitude of 
weight loss at 1 year is strongly (P < 0.0001) associated with improvements in glycaemia, 
triglycerides, blood pressure and HDL cholesterol. Participants who lost 5 to <10% of their body 
weight ([means ± SD] 7.25 ± 2.1 Kg) had higher odds of achieving a 0.5% point reduction in 
HbA1c (Odds Ratio (OR): 3.52 [95% CI: 2.81- 4.40]), a 40 mg/dL decrease in triglycerides (2.20 
[1.71-2.83]), a 5mg/dL increase in HDL cholesterol (1.69 [1.37- 2.07]), a 5-mmHg decrease in 
systolic blood pressure (1.56 [1.27-1.91]) and a 5-mmHg decrease in diastolic blood pressure 
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(1.48 [1.20-1.82]) (45). In summary, modest weight losses of 5 to <10% were associated with 
significant improvements in CVD risk factors at 1 year, with even greater benefits amongst those 
who lost more weight (48).    
2.2 Effect of Weight Loss on Diabetes   
According to Statistics Canada, there were 1,120,432 males and 890, 915 females aged 
12 y+ living with diabetes in 2014 (34). Currently, diabetes is the 6th leading cause of death, in 
both sexes, in Canada (35). Along with physical activity and diet, even modest weight loss has 
long term benefits in type II diabetes patients (46). Over 2.8 years of follow-up in the Diabetes 
Prevention Program (DPP), a three-arm randomized controlled trial, diabetes incidence in high-
risk adults was reduced by 31% with metformin and by 58% with intensive lifestyle intervention, 
compared with placebo (12). In addition, over the 10 year follow up since randomization to DPP, 
modest weight loss was maintained with metformin (12). The incidence rate of diabetes during 
the DPP was 11.0 cases per 100 person-years (95% CI: 9.8-12.3) in the placebo group, 7.8 (6.8-
8.8) in the metformin group, and 4.8 (4.1-5.7) in the intensive lifestyle group. However, in the 
follow-up, the 10-year incidence of diabetes was reduced by 18% (7–28) in the metformin group 
and 34% (24–42) in the lifestyle group compared with placebo (12). In a further analysis of 1079 
participants (25-84 y) of the DPP (mean 50.6 years, BMI 33.9 kg/m2), weight loss was found to 
be the dominant determinant of the reduced risk of diabetes (hazard ratio per 5-kg weight loss 
0.42 [95% CI: 0.35-0.51]; p< 0.0001). There was a 16% reduction in diabetes risk for every 
kilogram of weight loss, adjusted for changes in diet and physical activity. Moreover, there was a 
55% reduction in the risk of diabetes when weight loss exceeded 5 kg (17), and more than 90% 
reduction in the risk of diabetes in individuals who lost more than 5-7% and also met the dietary 
fat and physical activity goals (17).  
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2.3 Effect of Weight Loss on Hypertension  
There are 7.5 million people in Canada living with hypertension (18). According to the 
2014 and 2015 CHMS household and physical measures data, around one-quarter of adults aged 
20 to 79 had hypertension in Canada. For both sexes, average blood pressure significantly 
increases with age. The average blood pressure for males, 20 to 29 years old, increased from 
107/69 mmHg to 123/70 mmHg amongst males aged 70 to 79 (33). In addition, overweight and 
obese individuals were twice as likely to develop hypertension in comparison to individuals with 
normal weight (Normal weight: 12%; Over weight/Obese: 30%). Weight loss reduces blood 
pressure in individuals with overweight even if they are in the normal or high normal blood 
pressure range (39). During an 18-month follow-up period, in a randomized controlled clinical 
trial, a weight reduction program was shown to be an effective intervention for decreasing blood 
pressure in overweight adults with high-normal blood pressure (38). The average weight loss at 
6, 12, and 18 months of follow-up was 3.7, 2.7 and 1.6 kg for women and 6.5, 5.6 and 4.7 kg for 
men. The mean (±SE) in systolic pressure for the intervention participants compared with 
controls was -2.0±1.3 mmHg for women and -3.1±0.7 mmHg for men. For diastolic blood 
pressure, the corresponding change was -1.1±0.9 mmHg for women and -2.8±0.6 mmHg for men 
(38).  Taken together, these studies reinforce the close association between weight and blood 
pressure, and the clinical utility of weight loss therapy on hypertension risk within the outpatient 
setting. 
2.4 Major Classes of Weight Increase or Decrease Drugs 
Given the increasing prevalence of obesity in North America, primary and secondary 
prevention efforts are a public health priority (40).  However, obesity is multifactorial and 
difficult to treat, making relapse common. Of note, only 20% of individuals defined as 
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overweight (≥ 25 kg.m-2) are able to successfully maintain a 10% weight loss for at least 1 year 
(45). Because repeated weight loss followed by weight regain leads to a decrease in metabolic 
rate, this subsequently increases the efficiency of fat storage over time (6). While the benefits of 
medication use for chronic disease risk reduction are well known, some medications contribute 
to unhealthy weight gain, while others lead to weight loss (and further improve health). Others 
still may have no effect on weight. Amongst those trying to lose weight any unexpected 
(medication-induced) increase or decrease in weight may exacerbate the potential for weight loss 
and regain (e.g. weight cycling), and subsequently lead to poorer health over time. At present, 
there is no definitive understanding of the association of medication use with weight change as a 
barrier to weight loss within the clinical weight management setting. In the following section, a 
summary of weight- and “other” medication side-effects of the WMC medication classes, along 
with some specific medications in each class, are briefly discussed. Understanding the unique 
side effects of commonly used medications and their relationship to weight has the potential to 
foster knowledge and abilities, and consequently better goal setting for successful weight loss 
maintenance (28). 
Tricyclic Antidepressant Medications:  
One class of medication that has demonstrated a problematic body weight gain is tricyclic 
antidepressant medications. Depression is usually associated with a reduction in appetite and a 
subsequent decrease in body weight (14). Tricyclic antidepressant medications restore the mood 
and appetite (14), and the long-term administration of antipsychotic drugs induces weight gain, 
which afflicts up to 50% of patients (4). A comprehensive review of 81 articles by Allison et al. 
(1) showed the following mean increases in weight among newer antipsychotic agents: 
ziprasidone, 0.04 kg, risperidone, 2.10 kg, sertindole, 2.92 kg; olanzapine, 4.15 kg and clozapine, 
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4.45 kg. Antipsychotics induce weight gain through diverse mechanisms, including: i) an 
increase in appetite due to the interaction of antipsychotics with neural receptors to histamine, 
serotonin and dopamine, and; ii) antipsychotic-induced hyperprolactinaemia on gonadal adrenal 
steroids and insulin sensitivity (4), among others. Some of the other side effects of antipsychotic 
medications include anxiety, drowsiness, headache and insomnia (30).  
Diabetes Medications: 
Weight-related side-effects of diabetic medications are much more varied than 
antipsychotic medications: some diabetes medications cause weight loss, some cause weight gain 
and some do not cause a change in weight. For instance, Metformin causes weight loss (19, 9), 
Thiazolidinedione causes weight gain (15) and Glipizide, Biguanide and Acarbose do not cause a 
change in weight (30).  
Metformin promotes weight loss in patients with obesity and T2DM, largely through 
decreases in satiety (22). Clinically significant decreases in fasting plasma glucose concentration, 
insulin concentrations and plasma lipid levels are typically observed with regular Metformin 
consumption (11). Some of the other side effects of Metformin include diarrhea, gastrointestinal 
disorder, nausea and vomiting (30). 
Thiazolidinedione is derived from three compounds: pioglitazone (Actos), troglitazone 
(Rezulin) and rosiglitazone (Avandia) (19). Thiazolidinedione leads to weight gain through a 
range of mechanisms, including a decrease in plasma leptin levels and increased appetite. It has 
also been associated with changes in body fat distribution by contributing to a decrease in 
visceral fat and increased subcutaneous adipose fat storage (15). Troglitazone’s other side effects 
include anemia, oedema and cardiac problems and congestive heart failure. Finally, 
Rosiglitazone’s main side effects are anemia, nasopharyngitis and upper respiratory tract 
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infection, and; Pioglitazone’s side effects are hypoglycemia, upper respiratory tract infection and 
headache (30).  
Lipid Medications: 
Most of the lipid medications either induce a weight loss or have no effect on weight. 
According to the medication index Sider (http://sideeffects.embl.de/), out of 13 lipid medications 
listed by WMC patients, 4 induced weight loss, 9 were neutral, 4 had reports of weight gain and 
weight loss, and 2 had unknown effects. For instance, Cholestyramine, Ezetimibe, Simvastatin 
and Fenofibric induce weight loss and Colestipol, Colesevelam and Lovastatin have no effect on 
weight (30).  Available literature suggests that Ezetimibe significantly decreases body weight, 
waist circumference, BMI, total fat mass and subcutaneous and visceral fat (9). Furthermore, 
Ezetimibe significantly decreases the concentration of plasma LDL-apaB-100 by increasing its 
fractional catabolic rate (9). Ezetimibe’s other side effects are headache, upper respiratory tract 
infection and diarrhea (30). 
Blood Pressure Medications: 
In addition to the improved arterial blood pressure, patients undergoing treatment with 
Indapamide have shown significant weight loss (47). Indapamide’s other side effects are 
infection, headache and hypochloramia (30).  
Metoprolol significantly induces weight gain (mean [SD], 1.2 [0.2] kg), and has been 
shown to increase triglycerides (3). Previous research suggests that Metoprolol may exaggerate 
the weight gain amongst individuals living with overweight or obesity (25). Some of the other 
side effects of Metoprolol include cardiac failure, hypotension and bradycardia (30).  
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Thyroid Medications 
 Only one study to date (16) has examined the weight-related effects of Liothyronine, a 
thyroid medication. In this study a standard 1,000 calorie diet was administered to patients with 
obesity in a randomized cross-over design. Results suggest that from weeks 8 to 16 of the study, 
the use of Liothyronine resulted in an additional 0.39 kg/week of weight loss (16). Some of the 
side effects of liothyronine include tachycardia, cardiac problems, congestive heart failure, and 
hypertension (30).  
 
3.0 Study Rationale 
At present the possible association between chronic diseases and medication use with 
weight change within the clinical weight management setting is not well understood. Therefore, 
the purpose of this study is to explore variation in weight change outcomes amongst individuals 
with a range of comorbidities and medication classes. 
Research suggests that successful weight maintenance - intentional weight loss that has 
subsequently been maintained for at least 6 months - is associated with larger initial weight loss, 
reaching a self-determined goal weight, control of over-eating, and self-monitoring of behaviors 
(13). Weight maintenance is further associated with better coping strategies and ability to handle 
life stresses, social support, internal motivation to lose weight, self-efficacy, assuming 
responsibility in life, autonomy, and overall more psychological strength and stability (13). 
Because of the complex interplay between these psychological factors and the physiological 
changes associated with long-term weight gain, it is critical to understand how factors such as 
medication use may be impacting on weight change in the clinical setting. At the present time 
there is little information regarding the number and type of medications used by individuals 
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living with obesity (stage I, II, and III). Together, this information will provide perspective on 
medications and conditions that may be either barriers or promoters to weight loss success – 
whether through direct means - or by enhancing or impairing motivation and adherence to 
clinical lifestyle programming. 
 
4.0 Objectives 
Objective 1: To characterize the number of medications used by participants of the Wharton 
Medical Clinic (WMC) both overall, and by BMI category (overweight, obesity class I, II and 
III).  
Objective 2: To determine whether percentage weight change differs according to the 
therapeutic drug classes and by chronic diseases.  
Objective 3: To determine if the relationship between number of medications consumed is 
related to the achievement of a clinically significant weight loss (≥ 5%). 
 
5.0 Methods 
5.1 Wharton Medical Clinic 
Data is drawn from patients of the Wharton Medical Clinic (WMC), a medically 
supervised weight management centre with 6 locations in the Greater Toronto Hamilton Area. 
This referral-based clinic is comprised of a team of dietitians, medical doctors, and includes 
behavioral therapy and nutritional counseling, among other services. In so doing, the WMC is 
involved in the management of obesity to decrease diabetes and cardiovascular-related risk 
factors, such as high cholesterol and high blood pressure. The ultimate goal of the WMC is to 
improve the health and the quality of life of patients living with overweight and obesity.  
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The WMC is fully funded by the Ontario Health Insurance Plan (OHIP) and includes a 
weight management, brain, heart and diabetes clinic. All participants provided written informed 
consent for their information to be used.  
5.2 Participants 
Informed Consent Process:  
All patients were provided with details of the clinic and ongoing data collection at their 
first clinic visit. Patients were subsequently presented with a letter of written informed consent 
for their review. Patients were informed that they could withdraw consent at any time, and that 
regardless of their participation, there would not be any differences in the care provided by the 
clinic. This research is approved by the human participants’ research community of York 
University (Appendix A) and data for this analysis is accessed as a secondary analysis, with data 
extraction on December 5th, 2014. 
First Visit Measures: 
At the initial consultation, anthropometric measurements are taken (e.g. waist 
circumference, weight and height) and an exploratory electrocardiograph is administered. 
Patients are also asked to fill out a questionnaire regarding various aspects of their medical 
history, including their level of physical activity, diet, physical and psychological conditions 
(42). A registered dietitian also has a brief consultation with patients during their first visit to 
WMC to provide an overview of the program. A clinic physician then works with the patient to 
prescribe a personalized treatment plan to fit the patient’s needs and set a realistic weight 
management and lifestyle change goal for the patient. Following this, the patients are encouraged 
to attend the clinic every week to be weighed by the physician or the bariatric educator. Regular 
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contact is maintained between the patient and clinic, and weight management talks and 
continuing education are provided to the patient as needed (42).  
Sample Size 
Data for this analysis includes n=1913 participants who attended the clinic for ≥3 months.   
A three-month threshold was selected to ensure an adequate sample size to examine weight loss 
maintenance. Patients with a BMI ≤ 25kg.m-2 (n=2) and a weight change of 50.4 kg (n=1) were 
initially excluded. After excluding 381, 79 and 24 patients with missing education information, 
waist measurements, and smoking status, the final sample size was narrowed to 1426 patients 
(Figure 1).  
5.3 SIDER: Side Effect Resources  
In order to identify the weight-related side effects of all possible medications of existing 
clinic patients, the SIDER 4.1: side effect resource (http://sideeffects.embl.de/) was scanned. 
Side effects of each medication, along with any report of weight gain, neutral and weight loss 
were recorded (Appendix C). SIDER extracts this information from public documents and 
package inserts (30). Results were then cross-validated by a medical doctor (Dr. Sean Wharton), 
and a list of 153 medications was subsequently created to classify drugs into type II diabetes, 
lipid, blood pressure, thyroid, congestive heart failure, blood-thinner, Meridia, and cholesterol 
medications. In total, there were 21 type 2 diabetes, 19 lipid, 76 blood pressure, 6 thyroid, 33 
congestive heart failure, 3 blood-thinner, 2 weight loss (meridia and orlistat) and 6 cholesterol 
medications identified for the purposes of the current study.  
5.4 Study Variables 
Exposure Variable: Number and type of medications used by participants of the WMC and type 
of chronic diseases (self-reported baseline questionnaire and confirmed with physician).   
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Outcome Variable: Relative (%) and absolute (kg) amount of weight change and percentage 
achieving ≥ 5% weight loss over 3+ months of follow-up.  
Confounding Variables: Age, sex, waist circumference, education (less than high school, high 
school/GED, college, university), smoking status (current, former, never), average number of 
clinic visits and number of medications (0, 1, 2, 3, 4+). 
5.5 Statistical Analysis 
Descriptive analysis (proc univariate, proc freq (n, %)) is used to determine the number 
of medications used by participants of the WMC, both overall, and by obesity class (I to III).To 
determine whether the amount of percentage weight change differs according to the therapeutic 
drug classes and by chronic disease, multivariable logistic regression analysis was used to 
estimate the odds of achieving ≥ 5% weight loss by number of medications, and then stratified 
by cardiovascular related diseases. Model 1 is adjusted for age and sex and model 2 is adjusted 
for age, sex, education, waist circumference, smoking status, and average number of visits. 
General linear model analysis is also carried out to quantify the relationship between medication 
number and weight loss amongst males and females overall, and stratified by select chronic 
conditions. Due to a limited sample size, separate general linear analyses for patients with a 
history of stroke (0.7%) and heart attack (1%) was not possible. Statistical significance was set at 
alpha of 0.05 and all analyses were performed using SAS version 9.4 (SAS Institute Inc, Cary, 
NC., USA). 
 
6.0 Results 
The baseline characteristics for study participants are presented in Table 1. In total, 409 
males and 1017 females attended the clinic for 3+ months and are included in the final analysis. 
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On average, the sample is middle-aged (mean age: 51.6 (12.7) years old), with a waist 
circumference of 119.6 (11.2) cm and 13.3 (8.4) clinic visits. The majority of participants were 
white (87.2%), obesity class III (48.9%), and were never-smokers (54.4%). In addition, 31.6%, 
14.7%, 16.9%, 19.6% and 17.1% of the patients were taking 0, 1, 2, 3, 4+ medications 
respectively (Table 1). Over 3+ months of follow-up, average weight loss was 4.7 kg, and 40.5% 
of the sample achieved ≥ 5% weight loss. Of the 153 medications listed by WMC patients, 32 
medications had side effects associated with weight gain, 8 had complications of weight loss, and 
113 were weight neutral. 
Figure 2 illustrates that the percentage weight change was greatest amongst patients with 
a history of stroke (6.1%), heart attack (5.3%) and hypertension (4.8%). In addition to patients 
who were taking Meridia (4.8%), patients who were on blood pressure or cardiovascular 
medications also showed the highest percentage weight loss (4.5%) (Figure 3). Average number 
of medication intake increased with obesity classifications. Individuals identified as being over-
weight, obesity class I, II and III took an average number of 1.3, 1.6, 1.7 and 1.9 medications, 
respectively (Figure 4). Results also showed that only 9% of patients classified as overweight 
took 4+ medications versus 19% of the patients identified as class III obese. In addition, almost 
half of the patients who were overweight (44%) were taking no medications versus 29% of the 
patients identified as obese class III (data not shown). 
Because of the large discrepancy in sample size [Males: (n=409); Females: (n=1017)] 
and reported sex differences in previous research, separate generalized linear models were 
developed for men and women. In males, a significant relationship between medication number 
and weight loss was found with a p value of 0.02 but this relationship was non-significant 
amongst females. In addition, no significant relationship between medication number and weight 
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loss was found amongst females and males in subgroups of participants with diabetes, 
prediabetes, or hypertension (Table 2). Overall, average weight loss was greater in males (-6.4 
kg) in comparison to females (-4.1 kg).  
Logistic regression analysis revealed an inverse association between the number of 
medications reported and the % who were able to achieve ≥5% weight loss (Table 3). For 
instance, in model 1, individuals who reported taking 3 medications had 30% lower odds of 
achieving a ≥5% weight loss in comparison to the referent group (no prescription medication 
use).  
 
7.0 Discussion 
7.1 Findings 
Given the increasing prevalence of chronic diseases and consequent usage of medications 
(8), it is important to address the association between chronic diseases and medications with 
weight change in a clinical setting. This study demonstrated the greatest weight change 
percentage amongst patients with a history of stroke, hypertension and heart attack. In addition, 
patients who were taking blood pressure, cardiovascular medications and Meridia also showed 
the highest percentage weight change.  
This study also indicated that as the number of prescription medication intake increased, 
it became less likely that the patient achieved a clinically significant ≥ 5% weight loss. 
Additionally, although the findings did not reach statistical significance, as BMI increased, the 
number of prescription medications tended to increase as well. This makes it challenging to 
interpret the results in regards to patients living with obesity class III who are taking several 
medications, with different side effects, at the same time.  
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In addition, results of this paper illustrated that patients who attended WMC achieved a mean (± 
SD) weight loss of 4.7±11.2 kg, with almost 40.5% of the patients attaining a ≥ 5% weight loss. 
This is consistent with the previous research on the patients of the WMC attending the clinic for 
at least 3 months ([8.1± 6.1 visits and 5.4 ± 4.7 months) which reported a weight loss of (4.2 ± 
7.1 kg), with 32% and 9% of these patients achieving weight reductions of 5% or greater and 
10% or greater, respectively (43). Moreover, results of a cross-sectional and longitudinal study 
on community dwelling residents (n=885), aged 72 and older, found that participants consumed 
on average 2.2 (mean) ± 1.9 (standard deviation) medications (range 0-15) (2). This study 
reported a linear relationship between number of medication intake and weight loss. After 
adjustment for age, cognitive impairment, depressive symptoms, vision and hearing impairment, 
number of chronic diseases, number of medications, and number of hospitalizations in the 
previous year, the adjusted weight loss was 1.48 (95% CI=0.85-2.59) for those who were 
consuming two medications, 1.96 (1.08-3.54) for three or four medications, and 2.78 (1.38-5.60) 
for five or more medications (2). Even though the number of medications in this study is 
consistent with the number of medications taken by the patients of the WMC [1.3 (overweight), 
1.6 (class I), 1.7 (class II), 1.9 (class III)], the relationship between the number of medications 
and weight loss is contrary to the reported inverse relationship found in our study. For instance, 
in model 1, individuals who reported taking 3 medications had 30% lower odds of achieving a 
≥5% weight loss in comparison to the referent group (no prescription medication use). This may 
be due to the age difference between these two study samples (≥72 vs 51.6), setting of the studies 
(Urban Connecticut community vs medically supervised weight management center) or the BMI 
of the participants (Normal weight vs Obesity class II/III).  
 
17 
 
7.2 Study Limitations 
As with other secondary analyses, there are caveats to the validity and interpretation of study 
results. One of the main limitations of this study is that people who are on medications may not 
adhere to them fully (7, 10). Second, baseline questionnaire information may not be missing at 
random, and the exclusion of participants with incomplete covariate information may introduce 
bias and decrease overall generalizability to the broader clinic population. For instance, due to 
high missing frequency, variables such as income, ethnicity, current level of physical activity, 
drinking status, mental health status and weight perception were excluded which may obscure 
the overall relationship between weight loss and medication consumption. Additionally, there 
may not be sufficient data regarding WMC participants who gained weight (≥ 5% above baseline 
weight), since they are still on a weight loss program and due to the high dropout rate of this 
population. This information would have been valuable to help us understand the association 
between weight gain and medication classes better. Furthermore, although all WMC services are 
OHIP-eligible, participants must be referred by their family doctor and may therefore represent a 
more health conscious, and more motivated segment of the population living with obesity in 
Ontario (42, 26). Finally, there may be a referral bias in the first place because almost 86% of the 
WMC sample is comprised from white patients who may not be fully representative of the 
broader GTHA population from which patients were drawn. 
 
7.3 Implications and Future Directions 
A better understating of the possible association between  chronic conditions and medication 
classes with weight change is necessary so that personalized prescriptions can be made to 
patients according to their weight and medication use. This will ensure that the patients are 
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prepared for the possibility that their weight loss “goal” may not be achieved, and that one of the 
barriers may the medications that they are taking.  
7.4 Conclusion 
This paper demonstrated that as the number of medication intake increased it became less likely 
for the individual to achieve a ≥ 5% weight loss and that patients with a history of hypertension 
or heart attack; and who took blood pressure or cardiovascular medications showed the highest 
weight change percentage. Future qualitative work is necessary to understand how polypharmacy 
may be an explicit barrier to long-term weight maintenance within the clinic setting.  
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Extended Discussion 
 
A. Generalizability of the Results 
Gaining knowledge about the association between medications and chronic conditions 
with weight change is imperative to understanding how barriers to weight loss can be pro-
actively discussed as part of the general practitioner or bariatric physician initial consultation. 
Unfortunately, it is challenging to generalize the findings of this study to all the individuals 
living with obesity in Ontario. First, WMC patients are comprised from a healthier subset of the 
population. Of the 1426 patients, only 7.9%, 10.6%, 4.3%, 1.0% and 0.6% had a history of 
hypertension, diabetes, prediabetes, heart attack and stroke respectively. Second, eventhough the 
WMC is fully covered by OHIP and is assumed to be accessible to all the patients equally, there 
is a referral bias. To note, the majority of the patients who are referred to WMC are white 
(87.2%), women (71.3%). Moreover, this segment of the population overcame the transportation 
barrier and adhered to the program over ≥3 months of follow up. Hence this segment of the 
population may represent a more health conscious, motivated segment of the population living 
with obesity in Ontario (8, 3). Another issue that introduces bias and decreases the overall 
generalizability to the broader clinic population is that individuals with no reports of income, 
ethnicity, current level of physical activity, drinking status, mental health status and weight 
perception were excluded from the sample size. These variables may not be missing at random 
and may obscure the overall result. In addition, this study demonstrated that as the BMI 
categories increased from overweight to obesity class III, the number of medications that the 
patients took also increased. This makes it challenging to generalize the findings of this paper to 
patients who are classified in obesity class II or III categories. These patients take several 
medications, with different side effects, at the same time. Originally, this study was interested in 
20 
 
the issue of interaction between several medications. It was planned to investigate the effect of 
medications that induce weight gain versus medications that induce weight loss, separately, on 
weight change. Nevertheless, due to the way that coding was done in the data set, looking at this 
issue was not feasible and will remain as an issue to be looked at in future.  
B. Other Findings 
Even though the majority of the WMC patients were classified as obese class II (26.9%) 
or class III (48.9%), most of the patients did not experience comorbidities or functional 
limitations. This is due to the limitation of the current classification of obesity based on BMI in a 
clinical setting. The new clinical staging system, Edmonton Obesity Staging System (EOSS), 
that allows clinicians to demonstrate morbidities and clinical limitations associated with excess 
weight (5). According to this new staging system most of the WMC patients are categorized in 
obesity class III and EOSS stages 1 or 2. This healthier population, once again, makes it 
challenging to generalize the findings of this study to the overall population of the individuals 
living with obesity who are being categorized in the higher stages of the EOSS.    
Although cause and effect relationship cannot be inferred from this study, results 
demonstrated greatest percentage weight change amongst patients with a history of hypertension, 
stroke and heart attack and also amongst patients who were taking blood pressure, cardiovascular 
medication and Meridia. The higher percentage weight change may also be due to the differences 
in the patient “motivation” to lose weight. More recent and serious health events may provide 
motivation for weight loss (1). For example, these patients may have been told by their family 
physician that they need to lose weight for the serious condition that they have been diagnosed 
with.  
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Moreover, out of 153 medications rated by the clinical study lead (coauthor: S.W.) and 
SIDER, 32 and 25 medications induced weight gain, and 8 and 15 medications induced weight 
loss, respectively. In fact, 24.8% inter-rater agreement between the side effect information of 
medications (weight gain, loss, neutral) extracted from SIDER versus side effect information 
evaluated by Dr. Wharton was found. The low value of the Cohen’s kappa coefficient is partly 
due to the clinically meaningful ≥5% weight change (7, 9, 2) versus the public documents and 
package inserts as sources of information used by SIDER (6). At present, the appropriateness of 
either definition is unclear; however, given that it will ultimately be the physician who is 
managing the patient’s course of treatment, his or her interpretation of medication side effects 
will be deciding factor. Future work should attempt to understand (and quantify) physician 
knowledge of weight as a side-effect of medication use. 
In addition, further sensitivity analysis was carried out within disease specific groups of 
diabetes, prediabetes, stroke, heart attack and hypertension to find the odds of achieving ≥5% 
weight loss by number of medications. The results of this analysis was not significant for any of 
the chronic conditions (Appendix D-Table 3A).  
C. Implications and Future Directions  
A number of future directions warrant further investigation. First, there is a need to 
examine weight change separately in terms of medications that induce weight gain versus 
medications that induce weight loss. This facilitates a more precise personalized prescription to 
the patients and consequently leads to better weight change results. Second, to facilitate health 
behavior changes new theories are needed. A theoretical framework helps to improve the 
treatment by focusing assessments, directing the best practice interventions and ultimately 
improving patient outcomes. Integrated Theory of Health Behavior Change, ITHBC, proposes 
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that health behavior change can be improved by fostering knowledge and beliefs, increasing self-
regulation skills and abilities and enhancing social facilitation (4). This theory proposes that 
individuals are more likely to engage in the recommended health behaviors if they have 
information about and embrace health beliefs consistent with behavior (4). Knowledge about 
possible association between chronic diseases or medication use with weight loss would 
therefore fit within the knowledge portion of the ITBHC. Knowledge about chronic diseases and 
medication use as barriers to weight loss influences goal setting and consequently leads to a 
better distal outcome which is weight loss. By improving the knowledge piece in this theory, 
barriers to weight loss can be pro-actively addressed as part of the initial consultation and 
consequently more sustainable weight loss prescriptions can be set for the patients according to 
the chronic diseases that they experience or the medications that they consume. 
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Table1. Baseline Characteristics of WMC Patients 
 Male (N=409) Female (N=1017) Overall (N=1426) 
Age 52.3 (12.6) 50.8 (12.5) 51.6 (12.7) 
Ethnicity 
    White 
    South, East Asian/African  
    Other 
 
89.0 
4.9 
5.9 
 
86.5 
5.2 
8.2 
 
87.2 
5.1 
7.6 
Education 
    Less than high school 
    High school/GED 
    College 
    University 
 
10.0 
28.8 
30.6 
30.6 
 
6.3 
29.2 
38.7 
25.7 
 
 
7.4 
29.1 
36.4 
27.1 
BMI (kg/m2) 41.9 (8.6) 40.7 (7.8) 40.3 (8.8) 
Obesity class 
    Overweight 
    Obesity class I 
    Obesity class II 
   Obesity class III 
 
1.2 
21.2 
26.6 
50.9 
 
3.9 
20.9 
27.0 
48.1 
 
3.1 
21.0 
26.9 
48.9 
Average weight loss -6.4 (12.7) -4.1 (10.6) -4.7 (11.2) 
≥ 5% weight loss 41.2 40.5 40.5 
Waist circumference (cm) 133.6 (17.6) 118.1 (16.3) 119.6 (18.1) 
Hypertension (%) 
      
 
10.0 
 
6.9 
 
7.9 
Diabetes (%) 
      
 
10.7 
 
10.1 
 
10.6 
Pre-diabetes (%) 
      
 
4.4 
 
4.2 
 
4.3 
Stroke (%) 
      
 
0.7 
 
0.5 
 
0.6 
Heart-attack (%) 
      
 
1.2 
 
0.9 
 
1.0 
Smoke 
     Never 
     current 
     past 
 
49.6 
10.7 
49.6 
 
56.3 
9.2 
34.4 
 
54.4 
9.6 
35.9 
Average number of visits 14.9 (9.3) 12.6 (7.9) 13.3 (8.4) 
Number of medications  
     0 
     1 
     2 
     3 
     4+ 
  
22.5 
12.7 
17.1 
25.2 
22.5 
 
35.2 
15.5 
16.9 
17.4 
14.9 
            
31.6 
14.7 
16.9 
19.6 
17.1 
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Table 2. Relationship between Medication Number and Weight Loss Across Chronic 
Conditions 
 Average 
weight loss 
(Kg) 
N ß 
 
P r2 
Male  
   Diabetes 
   Prediabetes 
   Hypertension  
-6.4 
-4.4 
-4.0 
-5.7 
409 
44 
18 
41 
0.4 
1.5 
1.7 
1.7 
0.02 
0.6 
0.8 
0.5 
0.09 
0.2 
0.4 
0.2 
Female 
   Diabetes 
   Prediabetes 
   Hypertension 
-4.1 
-4.3 
-0.5 
-6.5 
1017 
103 
43 
70 
0.2 
0.7 
0.9 
0.9 
0.2 
0.4 
0.8 
0.8 
0.1 
0.1 
0.07 
0.4 
Adjusted for age, education, waist circumference, smoking status and average number of visits.  
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Table 3. Odds of ≥ 5% Weight Loss by Number of Medications  
 Model 1 Model 2 
OR 95% CI OR 95% CI 
0 medication 
(N=451) 
1.0 Referent 1.0 Referent 
1 medication 
(N=210) 
0.8 (0.6-1.1) 0.8 (0.6-1.2) 
2 medications 
(N=241) 
0.9 (0.7-1.2) 0.9 (0.6-1.2) 
3 medications 
(N=279) 
0.7 (0.6-0.9) 0.6 (0.4-0.9) 
4+ medications 
(N=245) 
0.8 (0.6-1.0) 0.7 (0.5-1.0) 
Model 1: Adjusted for age and sex. 
Model 2: Adjusted for age, sex, education, waist circumference, smoking status, and average number of visits. 
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Figure 1: Derivation of Final Analytic Sample 
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Figure 2: Percentage Weight Loss by Chronic Condition 
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Figure 3: Percentage Weight Loss by Medication Classes 
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Figure 4: Average Number of Medication Intake by BMI Classes 
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To:  Professor Jennifer Kuk 
 Department of Kinesiology  
 Faculty of Health 
 jennkuk@yorku.ca 
 
From:   Alison M. Collins-Mrakas, Sr. Manager and Policy Advisor, Research Ethics 
  (on behalf of Erin Ross, Vice-Chair, Human Participants Review Committee) 
 
Date:  Thursday, July 21, 2016 
 
Title:  Wharton Weight Management Clinic Longitudinal Study 
 
Risk Level:  Minimal Risk 
 
Level of Review: Delegated Review  
 
With respect to your research project entitled, “Wharton Weight Management Clinic Longitudinal Study”, the committee notes that, as 
there are no substantive changes to either the methodology employed or the risks to participants in and/or any other aspect of the research 
project, a renewal of approval re the proposed amendment(s) to the above project is granted.  
Any further changes to the approved protocol must be reviewed and approved through the amendment process by submission of an 
amendment application to the HPRC prior to its implementation.   
Ongoing research – research that extends beyond one year – must be renewed prior to the expiry date. 
Any adverse or unanticipated events in the research should be reported to the Office of Research ethics (ore@yorku.ca) as soon as possible. 
For further information on researcher responsibilities as it pertains to this approved research ethics protocol, please refer to the attached 
document, “RESEARCH ETHICS: PROCEDURES to ENSURE ONGOING COMPLIANCE”. 
Should you have any questions, please feel free to contact me at:  416-736-5914 or via email at:  acollins@yorku.ca. 
 
    Yours sincerely, 
    Alison M. Collins-Mrakas M.Sc., LLM 
    Sr. Manager and Policy Advisor,  
Office of Research Ethics 
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RESEARCH ETHICS: PROCEDURES to ENSURE ONGOING COMPLIANCE 
Upon receipt of an ethics approval certificate, researchers are reminded that they are required to ensure that the following 
measures are undertaken so as to ensure on-going compliance with Senate and TCPS ethics guidelines: 
 
1. RENEWALS:  Research Ethics Approval certificates are subject to annual renewal. It is the responsibility of 
researchers to ensure the timely submission of renewals.    
a. As a courtesy, researchers will be reminded by ORE, in advance of certificate expiry, that the certificate must 
be renewed. Please note, however, it is the expectation that researchers will submit a renewal application 
prior to the expiration of ethics certificate(s). 
 b. Failure to renew an ethics approval certificate (or to notify ORE that no further research involving human 
participants will be undertaken) may result in suspension of research cost fund and access to research 
funds may be suspended/ withheld. 
2. AMENDMENTS:  Amendments must be reviewed and approved PRIOR to undertaking/making the proposed 
amendments to an approved ethics protocol; 
        3. END OF PROJECT:  ORE must be notified when a project is complete; 
        4. ADVERSE EVENTS:  Adverse events must be reported to ORE as soon as possible; 
5. POST APPROVAL MONITORING: 
a. More than minimal risk research may be subject to post approval monitoring as per TCPS guidelines; 
b. A spot sample of minimal risk research may similarly be subject to Post Approval Monitoring as per TCPS 
guidelines. 
FORMS:  As per the above, the following forms relating to on-going research ethics compliance are available on the Research 
website: 
a. Renewal 
b. Amendment 
c. End of Project 
d. Adverse Event 
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Appendix B 
 WMC Questionnaire: 
 
Name: ____________________  Date: _____________________ 
 
 
Ethnicity: __________________         Sex:  M / F (Please circle) 
 
 
How long have you attended the Wharton Medical Clinic? ____________ 
 
Why do you think you have a weight problem? (Rank the top 3, with 1 being the most important) 
__ Over Eating   __ High Fat Diet  __ Junk Food 
__ Not Physically Active  __ Genetics   __ Environment  
__ Lack of Will Power   __ Medical Condition (ie. Thyroid, depression drugs, etc.) 
                                                     __ Other (specify):______________________ 
 
How much would you ideally like to weigh (ie. goal weight)? ___________ 
How long do you think it would take for you to attain that weight loss? ___________ 
 
How much weight loss do you think is realistic? ___________ 
How long do you think it would take for you to attain that weight loss? ___________ 
 
What is the minimal weight loss that you would be satisfied with? ___________ 
How long do you think it would take for you to attain that weight loss? ___________ 
 
Do you think you need to lose weight to become healthy?  Y     N 
If so, how much weight do you need to lose?  _____________ 
 
What do you think you need to do to achieve your goal weight loss? (Rank the top 3, with 1 
being the most important) 
  
__ Eat Less   __ Eat Better Food  __ Meal Replacement 
__ More Physical Activity   __ Genetic Modification  __ More Will Power   
__ Surgery   __ Weight Loss Drugs  __ Weight Loss Supplements  
__ Other (specify): _____________________________________________ 
 
Would you be satisfied with a small weight loss (ie. 5%) if your health and function was 
improved?   
Strongly Agree  Agree  Neutral  Disagree Strongly 
Disagree 
 
Would you be satisfied with a small weight loss (ie. 5%) if your health and function was 
normalized?   
Strongly Agree  Agree  Neutral  Disagree Strongly 
Disagree 
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If there was a pill that could permanently cure you of your weight problem tomorrow without 
dieting, exercise or surgery, how much would you be willing to pay for it?  
$_________________ 
 
Would you be willing to experience any of the following conditions or events if it meant you 
could be normal weight? 
Y     N  Blind       Y     N Severe Heart Disease  
Y     N  Paraplegic (Can’t walk)                 Y     N Never eat your favourite foods 
Y     N  Exercise for 1-2 hours per day       Y     N Life Sentence in Jail       
Y     N  Have only 5 more years to live      Y     N Live 20 years less than expected 
 
 
Would you be willing to stay at your current weight if it meant you could: 
 
Y     N  Be completely healthy (disease free) and fully functional 
Y     N  Be a millionaire/win the lottery    
Y     N  Be famous 
Y     N  Live forever    
 
Have you ever experienced weight discrimination, or had a negative experience because of your 
weight? Y     N 
 
If yes, please answer the following questions. (Circle All that apply, and Star the answer in 
regards to your worst experience). 
 
 When did it happen to you? Childhood Adolescence Adulthood 
 
 Type of experience: Verbal  Physical Discrimination  
             Physical Barrier (i.e. inappropriate seats, etc.) Other:____________________ 
 
 Age of the perpetrator:  Child  Adolescent Adult  N/A 
 
 Gender of the perpetrator:  Male  Female N/A 
 
 Their relation to you:             Peer/Friend Boyfriend/Girlfriend Parent   
 Child  Spouse  Sibling  Other Family    
 Stranger Physician Nurse  Other Health Professional  
 Boss/Supervisor  Teacher/Professor Other:___________________ 
 
Location: Home  Work  Medical Facility Public Place Mode  
Transportation  School  Other:____________________ 
 
Physical activity and sedentary time: 
 
What would you consider your current physical activity level to be: 
40 
 
Very Active                    Moderately Active          Average           Below Average      Very Poor 
 
Are you satisfied with the level of your physical activity?       Y    N 
 
How important was a change in physical activity in development of your obesity? 
Not at all Important Somewhat Important   Neutral         Important               Very 
Important 
 
Can you currently walk 4 miles briskly without fatigue?         Y     N 
 
Do you intend to change your physical activity in the next few months?     Y     N 
 
Do you have injuries or pain that may interfere with regular physical activity?           Y    N 
 
During the week, how many hours per day do you usually spend watching TV shows or videos? 
I don’t watch TV or videos            Less than 1 hour a day                   1-2 hours a day          
3-4 hours a day                             More than 4 hours a day 
 
During the weekend, how many hours per day do you usually spend watching TV shows or  
       videos? 
I don’t watch TV or videos            Less than 1 hour a day                 1-2 hours a day 
3-4 hours a day                             More than 4 hours a day 
 
During the week, how many hours per day do you usually use the computer to surf the Internet 
or  
Play video games? 
I don’t play video games or use the computer            Less than 1 hour a day          
1-2 hours a day                             3-4 hours a day    More than 4 hours a day 
 
During the weekend, how many hours per day do you usually use the computer to surf the  
Internet or play video games? 
I don’t play video games or use the computer            Less than 1 hour a day   
 1-2 hours a day   3-4 hours a day               More than 4 hours a day 
 
Diet History: 
 
Rate your current diet        
Very Poor          Poor          Average                  Good                   Very Good 
 
How often do you eat breakfast? 
7 days per week                       5-6 days per week                               3-4 days per week    
1-2 days per week           I do not eat breakfast   
 
 How often do you eat after 8 o’clock in the evening? 
 Regularly  Occasionally                     Never 
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Check if you eat (check all that apply): 
While cooking                        In the middle of the night                     While watching TV 
  
While reading                       When angry or depressed                     When bored    
In the car 
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Appendix C 
SIDER Excel Sheet (coauthor: S.W.) 
 
Generic Name  
 
Brand Name 
 
Weight Side 
effects  
Other Side Effects 
 
METFORMIN (GLUCOPHAGE) neutral, insignificant weight loss Diarrhea 
INSULIN  weight gain Infection 
PIOGLITAZONE  (DUETACT, ACTOS) weight gain Infection 
GLIMEPIRIDE  (AMARYL) weight gain Headache, influenza 
SULFONYLUREA  weight gain Skin reaction 
ROSIGLITAZONE  (AVANDIA) weight gain Anemia 
METFORMIN & ROSIGLITAZONE (AVANDAMET) weight gain Troubled breathing 
EXANTIDE (BYETTA) weight loss Agitation 
VILDAGLIPTIN  (GALVUS) weight neutral Asthenia, Dizziness 
GLIPIZIDE  weight gain Asthenia, Headache 
BIGUANIDE  weight neutral Anaphylactic shock 
GLYBURIDE  weight gain Swallowing problem 
GLYBURIDE & METFORMIN (GLUCOVANCE) weight gain Anxious feeling 
GLIPIZIDE  (GLUCOTROL) weight gain Asthenia, Headache 
MIGLITOL (GLYSET) weight neutral Bloated full feeling 
SITAGLIPTIN (JANUVIA) weight neutral Anxiety 
SITAGLIPTIN & METFORMIN (JANUMET) weight neutral Bloated feeling 
REPAGLINIDE (PRANDI) weight neutral Headache, Rhinitis 
ACARBOSE  (PRECOSE) weight neutral Constipation 
TROGLITAZONE  (Rezulin) weigh gain Anemia 
NATEGLINIDE  (STARLIX) weight neutral Infection 
CHOLESTYRAMINE  weight neutral Constipation 
COLESTIPOL  (COLESTID) weight neutral Abdominal pain  
COLESEVELAM  (WELCHOL) weight neutral Flatulence 
EZETIMIBE  (ZEITA) weight neutral Headache 
SIMVASTATIN (ZOCOR) weight neutral Infection 
SIMVASTATIN & EZETIMIBE  (VYTORIN) weight neutral Abdominal fullness 
FENOFIBRATE  (ANTARA, FENOGLIDE) weight neutral Abnormal liver  
FENOFIBRIC  (LOFIBRA, TRILIPIX) weight neutral Abnormal liver  
GEMFIBROZIL  (LOPID) weight neutral Dyspepsia 
ATORVASTATIN  (LIPITOR) weight neutral Infection, Diarrhea 
AMLODIPINE  (CADUET) weight neutral Headache, Fatigue 
FLUVASTATIN  (LESCOL) weight neutral Angiopathy 
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LOVASTATIN (MEVACOR) weight neutral Flatulence 
PRAVASTATIN  (PRAVACHOL) weight neutral Nausea 
ROSUVASTATIN (CRESTOR) weight neutral Headache 
NIACIN (ADVICOR) weight neutral Diarrhea, Nausea 
LOVAZA  weight neutral Infection, Influenza 
AMILORIDE  (MIDAMOR) weight neutral Hyperkaliemia 
BUMETANIDE  (BUMEX) weight neutral Hypochloremia 
CHLOROTHIAZIDE  (DIURIL) weight neutral Abdominal pain 
CHLORTHALIDONE  (HYGROTON) weight neutral Hypokalemia 
FUROSEMIDE  (LASIX) weight neutral Creatinine increase 
HYDROCHLOROTHIAZIDE  (HYDRODIURIL, ESIDRIX) weight neutral Infection 
INDAPAMIDE (LOZOL) weight neutral Infection 
SPIRONOLACTONE  (ALDACTONE) weight neutral Agranulocytosis 
BENAZEPRIL  (LOTENSIN) weight neutral Dizziness, Fatigue 
CAPTOPRIL (CAPOTEN) weight neutral Dizziness, Cough 
ENALAPRIL  (VASOTEC) weight neutral Headache, Dizziness 
FOSINOPRIL  (MONOPRIL) weight neutral Sexual dysfunction 
LISINOPRIL  (ZESTRIL, PRINIVIL) weight neutral Dizziness 
MOEXIPRIL  (UNIVASC) weight neutral Cough increased 
PERINDOPRIL   weight neutral Headache, Cough 
ACEON  weight neutral Headache, Cough 
QUINAPRIL (ACCUPRIL) weight neutral Chest pain, Diarrhea 
RAMIPRIL  (ALTACE) weight neutral Headache 
TRANDOLAPRIL  (MAVIK) weight neutral Blood urea increased 
CANDESARTAN  (ATACAND) weight neutral Kidney abnormality 
EPROSARTAN  (TEVETEN) weight neutral Infection 
IRBESARTAN  (AVAPRO) weight neutral Diabetics, Headache 
LOSARTAN  (COZAAR) weight neutral Infection 
TELMISARTAN  (MICARDIS) weight neutral Infection 
VALSARTAN (DIOVAN) weight neutral Diarrhea 
ACEBUTOLOL  (SECTRAL) weight gain Headache 
ATENOLOL  (TENORMIN) weight gain Depression 
BETAXOLOL  (KERLONE) weight gain Fatigue, Dyspepsia 
BISOPROLOL  weight gain Headache, Fatigue 
HYDROCHLOROTHIAZIDE  (ZIAC) weight neutral  Dizziness, Cough 
BISOPROLOL  (ZEBETA) weight gain Headache, Fatigue 
CARTEOLOL  (CARTROL) weight gain Arrhythmia 
METOPROLOL  (LOPRESSOR, TOPROL) weight gain Abdominal pain 
NADOLOL  (CORGARD) weight gain Dizziness, Fatigue 
PROPRANOLOL  (INDERAL) weight gain Sleep disorder 
SOTALOL  (BETAPACE) weight gain Fatigue, Dizziness 
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TIMOLOL  (BLOCADREN) weight gain Stinging 
ATENOLOL & CHLORTHALIDONE (TENORETIC) weight gain Cold arms and legs 
NADOLOL & 
BENDROFLUMETHIAZIDE (CORZIDE) weight gain Blurred vision 
PROPRANOLOL & 
HYDROCHLOROTHIAZIDE (INDERIDE) weight gain Abdominal pain 
TIMOLOL & 
HYDROCHLOROTHIAZIDE (TIMOLIDE) weight gain Chest pain 
BENAZEPRIL & 
HYDROCHLOROTHIAZIDE  (LOTENSIN) weight neutral Blurred vision 
Enalapril & 
HYDROCHLOROTHIAZIDE  (VASERETIC) weight neutral Blurred vision 
LISINOPRIL& 
HYDROCHLOROTHIAZIDE 
(PRINZIDE, 
ZESTORETIC) weight neutral Body aches or pain 
MOEXIPRIL & 
HYDROCHLOROTHIAZIDE (UNIRETIC) weight neutral Blurred vision 
AMLODIPINE (NORVASC) weight neutral Headache 
BEPRIDIL  weight neutral Nausea, Dizziness 
NISOLDIPINE (SULAR) weight neutral Headache 
VERAPAMIL (CALAN, ISOPTIN) weight neutral Constipation 
VERELAN  weight neutral Constipation IRBESARTAN & 
HYDROCHLOROTHIAZIDE (AVALIDE) weight neutral Headache, Sunburn 
LOSARTAN 
&HYDROCHLOROTHIAZIDE  (HYZAAR) weight neutral Dry mouth 
VALSARTAN & 
Hydrochlorothiazide (DIOVAN) weight neutral Flu-like symptoms 
AMLODIPINE & BENAZEPRIL (LOTREL) weight neutral Confusion 
CAS 76095-16-4 (LEXXEL) 
 
Headache 
TRANDOLAPRIL & VERAPAMIL (TARKA) weight neutral Chest pain, Chills 
DOXAZOSIN MESYLATE  (CARDURA) weight neutral Dizziness, Malaise 
PRAZOSIN HYDROCHLORIDE  weight neutral 
 PRAZOSIN  (MINIPRESS) weight neutral Dizziness  
PRAZOSIN  weight neutral Drowsiness 
POLYTHIAZIDE  weight neutral Agranulocytosis 
TERAZOSIN HYDROCHLORIDE  (HYTRIN) weight neutral Dizziness, Asthenia 
CLONIDINE HYDROCHLORIDE  (CATAPRES) weight neutral Infection 
CHLORTHALIDONE  weight neutral Hypokalemia 
CLONIDINE & CHLORTHALIDONE (CLORPRES) weight neutral Blood in urine 
GUANFACINE HYDROCHLORIDE  (TENEX) weight gain Dry mouth 
METHYLDOPA (ALDOMET) weight gain 
 CHLOROTHIAZIDE  weight neutral Agranulocytosis 
METHYLDOPA (ALDOCHLOR, ALDORIL) Agranulocytosis 
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CARVEDILOL  (COREG) weight gain Infection 
LABETALOL HYDROCHLORIDE  (NORMODYNE) weight gain Malaise, Fatigue 
IRBESARTAN  (AVAPRO) weight neutral Diabetics 
DILTIAZEM  (TIAZAC) weight neutral Edema  
METHIMAZOLE (TAPAZOLE) weight neutral Agranulocytosis 
LEVOTHYROXINE (LEVOXYL, SYNTHROID) weight loss Decreased urine  
LIOTHYRONINE (TRIIODOTHYRONINE, CYTOMEL) weight loss Angina pectoris 
LIOTRIX (THYROLAR) weight loss Chest pain 
THYROXINE  weight loss Abdominal cramps 
L-THYROXINE  (THYROXINE) weight loss Abdominal cramps 
FUROSEMIDE (Furocot) weight neutral Creatinine increased 
HYDRAZIDE  weight neutral 
 CAPTOPRIL (CAPOTEN) weight neutral Dizziness, Cough 
ENALAPRIL (VASOTEC) weight neutral Headache, Dizziness 
LISINOPRIL (ZESTRIL, PRINIVIL) weight neutral Blood urea increased 
BENAZEPRIL (LOTENSIN) weight neutral Dizziness, Fatigue 
RAMIPRIL (ALTACE) weight neutral Headache 
DIGOXIN (LANOXIN) weight neutral Dizziness, Diarrhea 
LOSARTAN (COZAAR) weight neutral Cough, Diarrhea 
CANDESARTAN (ATACAND) weight neutral Kidney abnormality 
TELMISARTAN (MICARDIS) weight neutral Arthritis 
VALSARTAN (DIOVAN) weight neutral Headache, Diarrhea 
IRBESARTAN (AVAPRO) weight neutral Diabetic, Headache 
BISOPROLOL (ZEBETA) weight gain Headache, Fatigue 
CARVEDILOL (COREG) weigh gain Infection 
CRYSTODIGIN    BUMETANIDE (BUMEX) weight neutral Hypochloremia 
TORSEMIDE (DEMADEX) weight neutral Headache, Dizziness 
HYDROCHLOROTHIAZIDE (HYDRODIURIL) weight neutral Infection 
METOLAZONE (ZAROXOLYN) weight neutral Dizziness 
ISOSORBIDE DINITRATE (DILATRATE) weight neutral Hemolytic anemia 
ISORBIDE MONONITRATE (IMDUR) weight neutral Sleep disturbance 
HYDRALAZINE (APRESOLINE) weight neutral Angina pectoris 
SPIRNOLACTONE (ALDACTONE) weight neutral Agranulocytosis 
AMLODIPINE (NORVASC) weight neutral Headache 
FELODIPINE (PLENDIL) weight neutral Abdominal pain 
DOBUTAMINE (DOBUTREX) weight neutral Angina pectoris 
MILRINONE (PRIMACOR) weight neutral Ventricular arrhythmia  
PLAVIX (CLOPIDOGREL) weight neutral Abdominal pain 
ASPIRIN  weight neutral Respiratory alkalosis 
SIBUTRAMINE (MERIDIA) weight loss Anaphylactic shock 
46 
 
ORLISTAT (XENICAL) weight loss Abdominal pain 
SIMVASTATIN  weight neutral Infection 
ATORVASTATIN (LIPITOR) weight neutral Infection, Diarrhea 
FLUVASTATIN (LESCOL) weight neutral GI disorder 
LOVASTATIN (MEVACOR, ALTOPREV) weight neutral Flatulence  
PRAVASTATIN (PRAVACHOL) weight neutral Musculoskeletal pain 
ROSUVASTATIN (CRESTOR) weight neutral Headache, Dizziness 
 
 
 
 
SIDER Excel Sheet 
 
Generic Name  
 
 
Brand Name 
 
 
Weight Side 
effects (S.W.)  
 
Weight Side 
effects 
(E.K.S.) 
METFORMIN (GLUCOPHAGE) neutral, insignificant weight loss weight loss 
INSULIN  weight gain mixed PIOGLITAZONE  (DUETACT, ACTOS) weight gain mixed 
GLIMEPIRIDE  (AMARYL) weight gain mixed 
SULFONYLUREA  weight gain weight neutral 
ROSIGLITAZONE  (AVANDIA) weight gain mixed 
METFORMIN & ROSIGLITAZONE (AVANDAMET) weight gain weight gain 
EXANTIDE (BYETTA) weight loss weight gain 
VILDAGLIPTIN  (GALVUS) weight neutral weight gain 
GLIPIZIDE  weight gain weight neutral BIGUANIDE  weight neutral weight neutral GLYBURIDE  weight gain weight gain GLYBURIDE & METFORMIN (GLUCOVANCE) weight gain weight neutral 
GLIPIZIDE  (GLUCOTROL) weight gain weight loss 
MIGLITOL (GLYSET) weight neutral weight neutral 
SITAGLIPTIN (JANUVIA) weight neutral weight neutral 
SITAGLIPTIN & METFORMIN (JANUMET) weight neutral weight neutral 
REPAGLINIDE (PRANDI) weight neutral weight loss 
ACARBOSE  (PRECOSE) weight neutral weight neutral 
TROGLITAZONE  (Rezulin) weigh gain weight gain 
NATEGLINIDE  (STARLIX) weight neutral weight loss 
CHOLESTYRAMINE  weight neutral weight loss 
COLESTIPOL  (COLESTID) weight neutral weight neutral 
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COLESEVELAM  (WELCHOL) weight neutral weight neutral 
EZETIMIBE  (ZEITA) weight neutral weight loss 
SIMVASTATIN (ZOCOR) weight neutral weight neutral 
SIMVASTATIN & EZETIMIBE  (VYTORIN) weight neutral weight neutral 
FENOFIBRATE  (ANTARA, FENOGLIDE) weight neutral mixed 
FENOFIBRIC  (LOFIBRA, TRILIPIX) weight neutral weight loss 
GEMFIBROZIL  (LOPID) weight neutral weight loss 
ATORVASTATIN  (LIPITOR) weight neutral mixed 
AMLODIPINE  (CADUET) weight neutral mixed 
FLUVASTATIN  (LESCOL) weight neutral weight neutral 
LOVASTATIN (MEVACOR) weight neutral weight neutral 
PRAVASTATIN  (PRAVACHOL) weight neutral mixed 
ROSUVASTATIN (CRESTOR) weight neutral weight neutral 
NIACIN (ADVICOR) weight neutral weight neutral 
LOVAZA  weight neutral weight neutral AMILORIDE  (MIDAMOR) weight neutral weight loss 
BUMETANIDE  (BUMEX) weight neutral weight neutral 
CHLOROTHIAZIDE  (DIURIL) weight neutral mixed 
CHLORTHALIDONE  (HYGROTON) weight neutral weight neutral 
FUROSEMIDE  (LASIX) weight neutral weight neutral 
HYDROCHLOROTHIAZIDE  (HYDRODIURIL, ESIDRIX) weight neutral weight neutral 
INDAPAMIDE (LOZOL) weight neutral weight loss 
SPIRONOLACTONE  (ALDACTONE) weight neutral weight neutral 
BENAZEPRIL  (LOTENSIN) weight neutral weight neutral 
CAPTOPRIL (CAPOTEN) weight neutral weight loss 
ENALAPRIL  (VASOTEC) weight neutral weight neutral 
FOSINOPRIL  (MONOPRIL) weight neutral mixed 
LISINOPRIL  (ZESTRIL, PRINIVIL) weight neutral mixed 
MOEXIPRIL  (UNIVASC) weight neutral weight neutral 
PERINDOPRIL   weight neutral weight neutral 
ACEON  weight neutral weight neutral 
QUINAPRIL (ACCUPRIL) weight neutral weight neutral 
RAMIPRIL  (ALTACE) weight neutral weight gain 
TRANDOLAPRIL  (MAVIK) weight neutral weight neutral 
CANDESARTAN  (ATACAND) weight neutral weight neutral 
EPROSARTAN  (TEVETEN) weight neutral weight neutral 
IRBESARTAN  (AVAPRO) weight neutral weight gain 
LOSARTAN  (COZAAR) weight neutral weight gain 
TELMISARTAN  (MICARDIS) weight neutral weight neutral 
VALSARTAN (DIOVAN) weight neutral weight neutral 
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ACEBUTOLOL  (SECTRAL) weight gain weight gain 
ATENOLOL  (TENORMIN) weight gain weight neutral 
BETAXOLOL  (KERLONE) weight gain mixed 
BISOPROLOL  weight gain weight gain HYDROCHLOROTHIAZIDE  (ZIAC) weight neutral weight neutral 
BISOPROLOL  (ZEBETA) weight gain weight gain 
CARTEOLOL  (CARTROL) weight gain weight neutral 
METOPROLOL  (LOPRESSOR, TOPROL) weight gain weight gain 
NADOLOL  (CORGARD) weight gain weight gain 
PROPRANOLOL  (INDERAL) weight gain weight neutral 
SOTALOL  (BETAPACE) weight gain weight neutral 
TIMOLOL  (BLOCADREN) weight gain weight loss 
ATENOLOL & 
CHLORTHALIDONE (TENORETIC) weight gain weight neutral 
NADOLOL & 
BENDROFLUMETHIAZIDE (CORZIDE) weight gain mixed 
PROPRANOLOL & 
HYDROCHLOROTHIAZIDE (INDERIDE) weight gain mixed 
TIMOLOL & 
HYDROCHLOROTHIAZIDE (TIMOLIDE) weight gain weight gain 
BENAZEPRIL & 
HYDROCHLOROTHIAZIDE  (LOTENSIN) weight neutral weight neutral 
Enalapril & 
HYDROCHLOROTHIAZIDE  (VASERETIC) weight neutral weight neutral 
LISINOPRIL& 
HYDROCHLOROTHIAZIDE 
(PRINZIDE, 
ZESTORETIC) weight neutral weight neutral 
MOEXIPRIL & 
HYDROCHLOROTHIAZIDE (UNIRETIC) weight neutral weight neutral 
AMLODIPINE (NORVASC) weight neutral mixed 
BEPRIDIL  weight neutral weight neutral NISOLDIPINE (SULAR) weight neutral mixed 
VERAPAMIL (CALAN, ISOPTIN) weight neutral weight neutral 
VERELAN  weight neutral weight neutral IRBESARTAN & 
HYDROCHLOROTHIAZIDE (AVALIDE) weight neutral weight neutral 
LOSARTAN 
&HYDROCHLOROTHIAZIDE  (HYZAAR) weight neutral weight neutral 
VALSARTAN & 
Hydrochlorothiazide (DIOVAN) weight neutral weight neutral 
AMLODIPINE & BENAZEPRIL (LOTREL) weight neutral weight neutral 
CAS 76095-16-4 (LEXXEL) 
 
weight neutral 
TRANDOLAPRIL & VERAPAMIL (TARKA) weight neutral weight neutral 
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DOXAZOSIN MESYLATE  (CARDURA) weight neutral mixed 
PRAZOSIN HYDROCHLORIDE  weight neutral  PRAZOSIN  (MINIPRESS) weight neutral weight neutral 
PRAZOSIN  weight neutral weight neutral 
POLYTHIAZIDE  weight neutral weight neutral 
TERAZOSIN HYDROCHLORIDE  (HYTRIN) weight neutral weight gain 
CLONIDINE HYDROCHLORIDE  (CATAPRES) weight neutral weight gain 
CHLORTHALIDONE  weight neutral weight neutral CLONIDINE & 
CHLORTHALIDONE (CLORPRES) weight neutral weight neutral 
GUANFACINE HYDROCHLORIDE  (TENEX) weight gain weight gain 
METHYLDOPA  (ALDOMET) weight gain weight gain 
CHLOROTHIAZIDE  weight neutral weight neutral METHYLDOPA (ALDOCHLOR, ALDORIL) weight gain 
CARVEDILOL  (COREG) weight gain mixed 
LABETALOL HYDROCHLORIDE  (NORMODYNE) weight gain weight neutral 
IRBESARTAN  (AVAPRO) weight neutral weight gain 
DILTIAZEM  (TIAZAC) weight neutral weight gain 
METHIMAZOLE (TAPAZOLE) weight neutral weight neutral 
LEVOTHYROXINE (LEVOXYL, SYNTHROID) weight loss mixed 
LIOTHYRONINE (TRIIODOTHYRONINE, CYTOMEL) weight loss weight neutral 
LIOTRIX (THYROLAR) weight loss weight gain 
THYROXINE  weight loss weight loss 
L-THYROXINE  (THYROXINE) weight loss weight loss 
FUROSEMIDE (Furocot) weight neutral weight neutral 
HYDRAZIDE  weight neutral  CAPTOPRIL (CAPOTEN) weight neutral weight loss 
ENALAPRIL (VASOTEC) weight neutral weight neutral 
LISINOPRIL (ZESTRIL, PRINIVIL) weight neutral mixed 
BENAZEPRIL (LOTENSIN) weight neutral weight neutral 
RAMIPRIL (ALTACE) weight neutral weight gain 
DIGOXIN (LANOXIN) weight neutral weight neutral 
LOSARTAN (COZAAR) weight neutral weight gain 
CANDESARTAN (ATACAND) weight neutral weight neutral 
TELMISARTAN (MICARDIS) weight neutral weight neutral 
VALSARTAN (DIOVAN) weight neutral weight neutral 
IRBESARTAN (AVAPRO) weight neutral weight gain 
BISOPROLOL (ZEBETA) weight gain weight gain 
CARVEDILOL (COREG) weigh gain mixed 
CRYSTODIGIN    
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BUMETANIDE (BUMEX) weight neutral weight neutral 
TORSEMIDE (DEMADEX) weight neutral weight neutral 
HYDROCHLOROTHIAZIDE (HYDRODIURIL) weight neutral weight neutral 
METOLAZONE (ZAROXOLYN) weight neutral weight neutral 
ISOSORBIDE DINITRATE (DILATRATE) weight neutral weight neutral 
ISORBIDE MONONITRATE (IMDUR) weight neutral mixed 
HYDRALAZINE (APRESOLINE) weight neutral weight loss 
SPIRNOLACTONE (ALDACTONE) weight neutral weight neutral 
AMLODIPINE (NORVASC) weight neutral mixed 
FELODIPINE (PLENDIL) weight neutral weight neutral 
DOBUTAMINE (DOBUTREX) weight neutral weight neutral 
MILRINONE (PRIMACOR) weight neutral weight neutral 
PLAVIX (CLOPIDOGREL) weight neutral weight neutral 
ASPIRIN  weight neutral weight neutral SIBUTRAMINE (MERIDIA) weight loss mixed 
ORLISTAT (XENICAL) weight loss weight loss 
SIMVASTATIN  weight neutral weight neutral 
ATORVASTATIN (LIPITOR) weight neutral mixed 
FLUVASTATIN (LESCOL) weight neutral weight neutral 
LOVASTATIN (MEVACOR, ALTOPREV) weight neutral weight neutral 
PRAVASTATIN (PRAVACHOL) weight neutral mixed 
ROSUVASTATIN (CRESTOR) weight neutral weight neutral 
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Appendix D 
Table 3A: Odds of ≥ 5% Weight loss by Number of Medications 
 Model 1 Model 2 
OR 95% CI OR 95%CI 
0 medication 1.0 Referent 1.0 Referent 
1 medication 0.8 (0.6-1.1) 0.8 (0.6-1.2) 
2 medications 0.9 (0.7-1.2) 0.9 (0.6-1.2) 
3 medications 0.7 (0.6-0.9) 0.6 (0.4-0.9) 
4+ medications 0.8 (0.6-1.0) 0.7 (0.5-1.0) 
Diabetes 
          0 
          1 
          2 
          3 
          4 
 
1.0 
1.3 
0.8 
1.0 
0.8 
 
Referent 
(0.9-1.9) 
(0.6-1.3) 
(0.7-1.5) 
(0.5-1.3) 
 
1.0 
1.7 
0.8 
0.9 
1.0 
 
Referent 
(0.7-4.2) 
(0.3-2.0) 
(0.3-2.8) 
(0.3-3.7) 
Prediabetes 
          0 
          1 
          2 
          3 
          4 
 
1.0 
1.3 
0.9 
1.0 
0.8 
 
Referent 
(0.9-1.9) 
(0.6-1.3) 
(0.7-1.5) 
(0.6-1.3) 
 
1.0 
1.7 
0.7 
0.9 
1.0 
 
Referent 
(0.7-4.1) 
(0.3-2.04) 
(0.3-2.6) 
(0.3-3.4) 
Stroke 
          0 
          1 
          2 
          3 
          4 
 
1.0 
1.4 
0.9 
1.0 
0.8 
 
Referent 
(0.9-1.9) 
(0.6-1.3) 
(0.7-1.5) 
(0.6-1.3) 
 
1.0 
1.6 
0.8 
0.9 
0.9 
 
Referent 
(0.6-4.0) 
(0.3-2.0) 
(0.3-2.6) 
(0.3-3.3) 
Heart attack 
          0 
          1 
          2 
          3 
          4 
 
1.0 
1.3 
0.9 
1.0 
0.8 
 
Referent 
(0.9-1.9) 
(0.6-1.3) 
(0.7-1.5) 
(0.6-1.3) 
 
1.0 
1.7 
0.7 
0.9 
0.9 
 
Referent 
(0.7-4.1) 
(0.3-2.0) 
(0.3-2.6) 
(0.3-3.4) 
Hypertension 
          0 
          1 
          2 
          3 
          4 
 
1.0 
1.4 
0.9 
1.0 
0.8 
 
Referent 
(0.9-1.9) 
(0.6-1.3) 
(0.7-1.5) 
(0.6-1.3) 
 
1.0 
1.7 
0.7 
0.9 
1.0 
 
Referent 
(0.7-4.1) 
(0.3-2.0) 
(0.3-2.6) 
(0.3-3.4) 
Model 1: Adjusted for age and sex. 
Model 2: Adjusted for age, sex, education, waist, smoking status, number of medications and 
average number of visits. 
